Global Radionuclide Drug Conjugate(RDC) Market Growth (Status and Outlook) 2024-2030

Global Radionuclide Drug Conjugate(RDC) Market Growth (Status and Outlook) 2024-2030

Radionuclide Drug Conjugate(RDC) are a form of drug designed and developed by coupling precise targeting molecules (monoclonal antibodies or peptides/small molecules, ligands) and powerful killing factors (nuclide, radioisotopes) together with linkers.

The global Radionuclide Drug Conjugate(RDC) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Radionuclide Drug Conjugate(RDC) Industry Forecast” looks at past sales and reviews total world Radionuclide Drug Conjugate(RDC) sales in 2022, providing a comprehensive analysis by region and market sector of projected Radionuclide Drug Conjugate(RDC) sales for 2023 through 2029. With Radionuclide Drug Conjugate(RDC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radionuclide Drug Conjugate(RDC) industry.

This Insight Report provides a comprehensive analysis of the global Radionuclide Drug Conjugate(RDC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radionuclide Drug Conjugate(RDC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radionuclide Drug Conjugate(RDC) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radionuclide Drug Conjugate(RDC) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radionuclide Drug Conjugate(RDC).

United States market for Radionuclide Drug Conjugate(RDC) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Radionuclide Drug Conjugate(RDC) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Radionuclide Drug Conjugate(RDC) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Radionuclide Drug Conjugate(RDC) players cover Novartis, Telix Pharmaceuticals, Lantheus, Curium, Yuanda Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Radionuclide Drug Conjugate(RDC) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Therapy
Diagnosis

Segmentation by Application:
Prostate Cancer
Neuroendocrine Cancer
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Therapy
Diagnosis

Segmentation by Application:
Prostate Cancer
Neuroendocrine Cancer
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Telix Pharmaceuticals
Lantheus
Curium
Yuanda Pharmaceuticals
China Tongfang Pharmaceuticals
Dongcheng Pharmaceuticals
Kelun Biotech
Hengrui
Bayer
Zhihe Biotechnology
Fulian Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.